South Korean drug firm SK Biopharmaceuticals is expected to raise at least 5 trillion won ($4.25 billion) through a planned share sale, analysts said Nov. 25.
The company said that XCOPRI has won approval from the US Food and Drug Administration for the treatment of partial-onset seizures in adults.
![]() |
Following the FDA approval, SK Biopharmaceuticals will likely speed up its IPO, with its shares slated to be listed early next year, according to them.
SK Biopharmaceuticals, a biopharmaceutical unit of South Korean conglomerate SK Group, submitted a preliminary application for an initial public offering to the Korea Exchange late last month.
SK Securities estimated in a recent research note that the corporate value of SK Biopharmaceuticals, wholly owned by SK Holdings, would reach about 6.2 trillion won.
In an August report, Korea Investment & Securities expected the market capitalization of SK Biopharmaceuticals to range from 5 trillion won to 10 trillion won.
By Ram Garikipati and newswires (ram@heraldcorp.com)